4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-054838
Chief Executive Officer sold 25,000 shares at an average $54.81 ($1,370,191)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Option exercise | +19,582 | $16.21 | $317,424 | 309,861 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Option exercise | +5,418 | $19.12 | $103,592 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Sale | −2,500 | $52.73 | $131,830 | 312,779 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Sale | −4,000 | $54.06 | $216,254 | 308,779 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Sale | −11,312 | $54.97 | $621,774 | 297,467 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Sale | −7,188 | $55.69 | $400,333 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Option exercise · Stock Option (Right to Buy) | −19,582 | 13,751 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2022-10-26 | Option exercise · Stock Option (Right to Buy) | −5,418 | 254,582 | D | ||
| Open-market sales · 25,000 sh · avg $54.81 · $1,370,191 | |||||||
Loading xslF345X03/doc4.xml…